Skip to main content

Table 1 Cell cycle progression of MSTO-211H cells treated with ZOL and/or Ad-delE1B55

From: Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma

Time (hrs)

Treatment

Cell cycle distribution (% ± SE)

Sub-G1

G1

S

G2/M

>4 N

24

(−)

2.04 ± 0.04

58.80 ± 0.20

18.17 ± 0.24

20.67 ± 0.31

0.81 ± 0.06

 

Ad-LacZ

2.90 ± 0.16

57.30 ± 0.19

17.59 ± 0.22

20.97 ± 0.26

1.83 ± 0.04

 

Ad-delE1B55

2.61 ± 0.16

55.29 ± 0.07

20.41 ± 0.11

20.08 ± 0.27

2.22 ± 0.11

 

ZOL

2.47 ± 0.05

57.47 ± 0.10

18.34 ± 0.27

20.70 ± 0.22

1.62 ± 0.09

 

ZOL + Ad-LacZ

3.58 ± 0.17

55.98 ± 0.16

17.94 ± 0.17

20.84 ± 0.10

2.22 ± 0.08

 

ZOL + Ad-delE1B55

3.72 ± 0.05

53.99 ± 0.11

20.53 ± 0.23

19.42 ± 0.35

3.00 ± 0.09

48

(−)

1.73 ± 0.07

76.54 ± 0.12

8.20 ± 0.03

12.59 ± 0.08

1.18 ± 0.04

 

Ad-LacZ

1.37 ± 0.08

75.90 ± 0.38

8.60 ± 0.16

12.55 ± 0.33

1.82 ± 0.03

 

Ad-delE1B55

12.25 ± 0.04

51.87 ± 0.21

12.47 ± 0.13

21.56 ± 0.19

2.32 ± 0.03

 

ZOL

3.82 ± 0.08

76.77 ± 0.43

6.70 ± 0.09

11.31 ± 0.33

1.60 ± 0.01

 

ZOL + Ad-LacZ

2.81 ± 0.11

76.08 ± 0.33

7.47 ± 0.12

11.95 ± 0.13

1.96 ± 0.06

 

ZOL + Ad-delE1B55

19.69 ± 0.18a

47.47 ± 0.19a

15.42 ± 0.44a

15.23 ± 0.35

2.69 ± 0.16

72

(−)

0.96 ± 0.02

87.55 ± 0.01

3.77 ± 0.13

7.26 ± 0.19

0.59 ± 0.05

 

Ad-LacZ

1.46 ± 0.10

87.58 ± 0.30

2.75 ± 0.05

7.79 ± 0.14

0.51 ± 0.03

 

Ad-delE1B55

22.52 ± 0.07

43.47 ± 0.18

11.57 ± 0.14

12.89 ± 0.23

10.14 ± 0.23

 

ZOL

11.19 ± 0.08

76.77 ± 0.28

3.45 ± 0.08

7.93 ± 0.20

0.81 ± 0.12

 

ZOL + Ad-LacZ

6.44 ± 0.03

80.27 ± 0.15

3.04 ± 0.04

9.66 ± 0.13

0.78 ± 0.04

 

ZOL + Ad-delE1B55

35.52 ± 0.05a

24.06 ± 0.30a

13.89 ± 0.13b

11.83 ± 0.21

15.41 ± 0.19

96

(−)

1.03 ± 0.07

87.25 ± 0.01

4.43 ± 0.03

6.93 ± 0.06

0.50 ± 0.03

 

Ad-LacZ

1.16 ± 0.06

87.36 ± 0.28

3.34 ± 0.17

7.65 ± 0.11

0.68 ± 0.04

 

Ad-delE1B55

12.14 ± 0.27

53.92 ± 0.29

11.93 ± 0.06

13.21 ± 0.27

9.32 ± 0.31

 

ZOL

9.32 ± 0.11

80.72 ± 0.21

3.98 ± 0.06

5.73 ± 0.07

0.40 ± 0.07

 

ZOL + Ad-LacZ

8.93 ± 0.17

78.40 ± 0.17

4.22 ± 0.14

7.92 ± 0.13

0.79 ± 0.04

 

ZOL+ Ad-delE1B55

40.75 ± 0.08a

21.50 ± 0.21a

14.26 ± 0.11b

10.58 ± 0.12

13.59 ± 0.18b

  1. Cells were treated with ZOL (10 μM) and/or either Ad-delE1B55 or Ad-LacZ (4.5 × 103 vp/cell) and cultured for 24–96 h. Cell cycle profiles were analyzed with flow cytometry. Averages with SEs are shown (n = 3)
  2. a p < 0.01, b p < 0.05; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells